All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-la-Neuve, BE and Noopur Raje, Massachusetts General Hospital, Boston, US. In this podcast, they discuss the topic: Managing infections with novel immunotherapies: Prevention, treatment, and impact on the quality of life of patients with multiple myeloma.
Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM
Raje and Delforge discuss the management of infections with novel immunotherapies, including: monoclonal antibodies, antivirals, risk of infection, intravenous immunoglobulin, and the impact of COVID-19. This podcast closely links to our latest editorial theme, in which the Multiple Myeloma Hub explores how to manage adverse events from novel agents, with our first article examining proteasome inhibitors and cardiovascular events.
Subscribe to get the best content related to multiple myeloma delivered to your inbox